Core Viewpoint - Investors in Kyverna Therapeutics, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred following the company's initial public offering in February 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Kyverna Therapeutics failed to disclose adverse data related to one of its clinical trials, which misled investors regarding the company's business and operational prospects [3]. - The complaint highlights that the defendants' positive statements about the company's performance lacked a reasonable basis due to the withholding of critical adverse data [3]. Group 2: Participation Information - Investors who suffered losses in Kyverna Therapeutics are encouraged to contact the Law Offices of Howard G. Smith before February 7, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit